Dr. Tamojit Chaudhuri is a highly accomplished Senior Medical Oncologist at Faridabad and Delhi NCR with 12 years of experience and expertise in treating all types of solid and hematological malignancies. He has a special interest in Precision Oncology, Immunotherapy and CAR T-cell therapy. His key areas of interest in the field of Oncology include – Breast cancer, Lung cancer, Gastrointestinal cancers, Gynecological cancers, and Lymphomas. He has more than 20 national and international presentations and 50 publications in national and international peer-reviewed journals.
Speciality
Precision Oncology
Immunotherapy
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecological Cancer
Head and Neck Cancer
Brain Tumors
Sarcoma
Lymphoma
Multiple Myeloma
Chronic Leukemia
Education
European Society Board certification in Medical Oncology (ECMO)
DM (Gold Medalist), Kidwai Memorial Institute of Oncology, Bengaluru
MRCP SCE (Medical Oncology)
MD, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
MBBS, Calcutta National Medical College, Kolkata
Experience
Senior resident, Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru
Consultant, Department of Medical Oncology, Apollo Gleneagles Hospital, Kolkata
Senior consultant and HOD, Department of Medical Oncology, Meherbai Tata Memorial Hospital, Jamshedpur
Awards & Recognition
ISMPO-TYSA young scholar award in Medical Oncology 2018
RGUHS Gold Medal in Medical Oncology 2018
ISMPO-COPE gold medal examination in Medical Oncology 2018 (at Cancer Institute Adyar) – 2nd prize
1st prize in 36th and 38th ICON Quiz (in 2017 and 2018)
Best poster award in ESMO-ASIA 2017, at Singapore
Membership
Indian Society of Medical and Pediatric Oncology (ISMPO)
American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
Immuno-Oncology Society of India (I-OSI)
Other Information
Research & Publications:
Chaudhuri T, Bankira J, Upadhyay AK, et al. Efficacy and Safety of First-Line Palliative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) in HER2-Negative Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Institutional Real-World Experience from Eastern India. South Asian J Cancer 2025;14(2):265-270.
T Chaudhuri, A Upadhyay, J Bankira, R Panda, V Pandey, S Mitra. First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India. Annals of Oncology 2023, ESMO ASIA 2023 abstract number 241P.
Chaudhuri T. Role of predictive biomarkers and tumor mutational profile in selecting patients with platinum-refractory head-and-neck cancers for immune checkpoint inhibitor monotherapy: Where do we stand? Cancer Res Stat Treat 2022;5:781-2.
Chaudhuri T. Single-agent bendamustine in recurrent and/or metastatic head-and-neck squamous cell carcinoma: Are we ready for a prospective study? Cancer Res Stat Treat 2023;6:158-9.
Rudresha AH, Chaudhuri T, Lakshmaiah KC, Babu G, Lokesh KN, Rajeev LK. Primary central nervous system lymphoma in immunocompetent patients: A regional cancer center experience. South Asian J Cancer 2017;6:165-8.
Rudresha AH, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Jacob LA, et al. Induction chemotherapy in technically unresectable locally advanced T4a oral cavity squamous cell cancers: Experience from a regional cancer center of South India. Indian J Med Paediatr Oncol 2017;38:490-4.
Suresh Babu MC, Chaudhuri T, Babu KG, Lakshmaiah KC, Lokanatha D, Jacob LA, et al. Metastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases. South Asian J Cancer 2017;6:118-21.
Babu KG, Chaudhuri T, Lakshmaiah KC, Dasappa L, Jacob LA, Suresh Babu MC, et al. Modified ECF regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A phase II study. South Asian J Cancer 2018.
Babu KG, Chaudhuri T, Lakshmaiah KC, Dasappa L, Jacob LA, Babu M, et al. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5- fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Indian J Cancer 2017;54:47-51.
Book An Appointment
Need help with the appointment?
Share your details and we'll quickly assist you.
Your request has been submitted, our team will contact you soon.
You agree to ensure that any information provided by you shall be complete and accurate. You shall not at any time provide us with information which is false, inaccurate, misleading, obsolete or deceptive. If the information is found false/ deceptive/inaccurate/misleading, AHL holds right to cancel the appointment/transaction and refund/stop the payment.
